↑ 疾患リストへ ← 戻る

 266. 家族性地中海熱 [臨床試験数:16,薬物数:14(DrugBank:6),標的遺伝子数:14,標的パスウェイ数:52] 

Searched query = "Familial mediterranean fever"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN0000325572018/09/015 November 2019An open-label continuation trial of tocilizumab for familial Mediterranean fever (FMF) with colchicine ineffective or intoleranceAn open-label continuation trial of tocilizumab for familial Mediterranean fever (FMF) with colchicine ineffective or intolerance - An open-label continuation trial of tocilizumab for familial Mediterranean feverfamilial Mediterranean feverTocilizumabDepartment of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesRecruiting12years-old76years-oldMale and Female24Not selectedJapan
2NCT03563300September 1, 201829 April 2019Gluten-related Disorders in Familial Mediterranean Fever PatientsGluten-related Disorders in Patients Affected With Familial Mediterranean FeverNot-celiac Wheat Sensitivity (NCWS);Familial Mediterranean Fever (FMF)Other: Wheat flour;Other: Placebo ComparatorUniversity of PalermoNot recruiting18 Years65 YearsAll8N/AItaly
3NCT03446209April 23, 201829 April 2019Tocilizumab for the Treatment of Familial Mediterranean FeverTocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept StudyFamilial Mediterranean FeverDrug: 0.9% physiological saline;Drug: Tocilizumab Infusion RoAcemtra (EU)University Hospital TuebingenRecruiting18 Years64 YearsAll30Phase 2Germany
4JPRN-UMIN0000280102018/03/0122 July 2019Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean feverRandomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever - Clinical trial of Tocilizumab for colchicine-resistant familial Mediterranean feverfamilial Mediterranean feverTocilizumab
Placebo
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical SciencesNot Recruiting12years-oldNot applicableMale and Female24Not selectedJapan
5EUCTR2016-004505-13-DE27/11/201730 April 2018Tocilizumab for the Treatment of Familial Mediterranean FeverTocilizumab for the Treatment of Familial Mediterranean Fever – A randomized, doubleblind, phase II proof of concept study-TOFFIFE - Tocilizumab for the Treatment of Familial Mediterranean FeverAdult patients with Familial Mediterranean Fever, who have active disease
MedDRA version: 20.0 Level: PT Classification code 10016207 Term: Familial mediterranean fever System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: RoActemra® 20mg/ml Konzentrat
CAS Number: 375823-41-9
Other descriptive name: TOCILIZUMAB
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 8-
Pharmaceutical form of the placebo: Infusion
Route of administration of the placebo: Intravenous use
University Hospital TuebingenAuthorisedFemale: yes
Male: yes
30Phase 2Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03210610October 19, 201711 June 2018Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) PatientsMeasurement of Colchicine Levels in the Serum of FMF PatientsFMF;Colchicine Resistance;Colchicine ToxicityDiagnostic Test: colchicine level measurementSheba Medical CenterRecruiting18 YearsN/AAll80Phase 4Israel
7EUCTR2017-001678-40-Outside-EU/EEA22 May 2017An extension study of safety of canakinumab in Japanese patients with periodic fever syndromesAn extension study of safety of canakinumab in Japanese patients with periodic fever syndromesThree disease of periodic fever syndromes, TNF receptor Associated Periodic Syndrome (TRAPS), Hyper IgDSyndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever (FMF
MedDRA version: 20.0 Level: SOC Classification code 10010331 Term: Congenital, familial and genetic disorders System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: Ilaris
Pharmaceutical Form: Solution for injection
INN or Proposed INN: CANAKINUMAB
CAS Number: 914613-48-2
Current Sponsor code: ACZ885
Concentration unit: mg/kg milligram(s)/kilogram
Concentration type: equal
Concentration number: 4-
Novartis pharma AGNot AvailableFemale: yes
Male: yes
4Phase 3Japan
8NCT02175589June 201419 February 2015Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene MutationControlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene MutationFamilial Mediterranean FeverOther: Colchicine CessationRambam Health Care CampusSchneider Children's HospitalRecruiting2 Years18 YearsBoth80Phase 2Israel
9NCT02021084December 201317 October 2016The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.Familial Mediterranean Fever (FMF )Dietary Supplement: probiotic;Dietary Supplement: PlaceboRambam Health Care CampusNot recruiting5 Years18 YearsBoth0N/A
10NCT01705756November 201216 December 2017Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean FeverA Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean FeverFamilial Mediterranean FeverDrug: KineretSheba Medical CenterNot recruiting18 Years65 YearsAll25Phase 3Israel
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02602028April 201123 November 2015The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMFThe Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized TrialFamilial Mediterranean FeverDrug: colchicineGulhane Military Medical AcademyNot recruiting5 Years16 YearsBoth79Phase 4Turkey
12NCT01148797December 201028 November 2016Evaluate the Safety and Efficacy of Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean Fever (FMF)A 6 Month Phase 2, Multi-Center, Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Treatment With Canakinumab in Pediatric Patients With Colchicine Intolerant or Colchicine Resistant Familial Mediterranean FeverColchicine Resistant/Intolerant Familial Mediterranean FeverDrug: CanakinumabNovartis PharmaceuticalsNot recruiting4 Years20 YearsBoth15Phase 2Israel
13NCT01075906August 201019 February 2015Pharmacokinetics Study of Colchicine in Familial Mediterranean Fever (FMF) PatientsAn Open-label, Parallel-group, Multiple-Dose, Pharmacokinetic and Safety Study of Colchicine Pediatric Formulation in Pediatric and Adult Patients With FMFFamilial Mediterranean FeverDrug: colchicine sprinkle capsulesMutual Pharmaceutical Company, Inc.Not recruiting2 Years65 YearsBoth75Phase 1United States;Armenia;Israel;Turkey
14NCT01088880April 201019 February 2015Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverAn Open-label, Exploratory Study to Establish the Safety and Efficacy of 3 Months Treatment With Canakinumab in Patients With Colchicine Resistant Familial Mediterranean FeverFamilial Mediterranean FeverDrug: CanakinumabNovartis PharmaceuticalsNot recruiting12 Years75 YearsBoth10Phase 2Turkey
15NCT00582907August 200819 October 2017Rilonacept for Treatment of Familial Mediterranean Fever (FMF)Phase 2 Study of IL-1 Trap (Rilonacept) for Treatment of Familial Mediterranean Fever (FMF)Familial Mediterranean FeverDrug: Rilonacept;Drug: PlaceboThe Cleveland ClinicNot recruiting4 YearsN/AAll14Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00094900October 200419 October 2017Interleukin-1 Trap to Treat Autoinflammatory DiseasesContinuation of a Pilot Open-Label Study of IL 1 Trap in Adult Subjects With Autoinflammatory Diseases: A Therapeutic Approach to Study PathogenesisInflammation;Familial Mediterranean Fever;Still's Disease, Adult-OnsetDrug: IL-1 TrapNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Not recruiting18 YearsN/AAll11Phase 2United States

先頭へ